iFAST Diagnostics Secures £5M to Bring 3-Hour Antibiotic Testing to the Global Market

A Platform Built for Speed in a Field Defined by Waiting

At the heart of the investment case is a technology that directly addresses one of medicine's most dangerous bottlenecks. When a patient arrives with a severe bacterial infection, clinicians need to know which antibiotic will work. The current gold-standard methods rely on culturing bacteria, a process that typically takes 48 to 72 hours to deliver results. In that time, doctors may prescribe broad-spectrum antibiotics, a practice that can be ineffective against resistant strains and contributes to the wider AMR crisis. iFAST's platform uses a phenotypic approach that measures bacterial growth at the single-cell level, a method the company says is both low-cost and high-throughput.

The system's performance targets are ambitious. The platform can produce results from a positive blood culture bottle in under three hours . When working with the more complex matrix of a raw urine sample, the turnaround time extends to three to four hours . This represents a reduction in waiting time of up to 95% compared to conventional processes, offering a clear clinical advantage for severe conditions like sepsis and urinary tract infections, where every hour without targeted therapy can worsen patient outcomes.

Targeting a $4 Billion Market with an AMR-Focused Pitch

iFAST is aiming its technology squarely at the global AST market, which it estimates to be worth $4 billion and growing . This market is being pushed by two converging forces: the steady rise in antimicrobial resistance, which the World Health Organization has classified as one of the top ten global public health threats, and a regulatory environment that is increasingly demanding faster diagnostic stewardship. Hospitals and health systems are under pressure to demonstrate that they are using antibiotics judiciously, and a three-hour test provides an auditable, rapid decision point that a three-day test never could.

Investor conviction in the company's market position was demonstrated by the oversubscribed nature of its previous seed round . The involvement of specialist health-tech funds like KHP Ventures in the 2024 round and Meridian Health Ventures in the most recent raise signals a belief within the sector that iFAST's platform is not merely an incremental improvement, but a step change in speed that can be integrated into existing clinical workflows.

The fresh injection of capital will be deployed across three critical fronts: accelerating commercial activities, scaling the manufacturing of its testing systems, and pursuing the necessary regulatory approvals to enter the UK market, with subsequent launches planned for the EU and US . For a company that was founded in just 2022, the aggressive timeline and rapidly expanding investor base suggest the industry sees a closing window to get ahead of the AMR curve—and a three-hour test as the key.